Impact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplant

[1]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[2]  M. Pasquini,et al.  Acute graft-versus-host disease: a bench-to-bedside update. , 2014, Blood.

[3]  M. Patnaik,et al.  Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning , 2013, Bone Marrow Transplantation.

[4]  Yu-Hong Chen,et al.  Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome , 2013, Leukemia & lymphoma.

[5]  J. Bolaños-Meade,et al.  Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  G. Specchia,et al.  Outcome of allogeneic peripheral blood stem cell transplantation by donor graft CD3+/Tregs ratio: a single-center experience. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  C. Flowers,et al.  Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: res , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  Stephanie J. Lee,et al.  Economics of hematopoietic cell transplantation. , 2012, Blood.

[9]  M. Horowitz,et al.  MHC-Resident Variation Affects Risks After Unrelated Donor Hematopoietic Cell Transplantation , 2012, Science Translational Medicine.

[10]  J. P. McCoy,et al.  Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation , 2012, Haematologica.

[11]  W. Hogan,et al.  Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  R. Storb,et al.  Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs , 2011, Haematologica.

[13]  S. E. Jacobsen,et al.  Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors , 2011, The Journal of experimental medicine.

[14]  J. Wagner,et al.  Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  S. Ansell,et al.  Day 15 peripheral blood lymphocyte/monocyte ratio post-autologous peripheral hematopoietic stem cell transplantation and survival in diffuse large B-cell lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Stirewalt,et al.  Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  J. Wagner,et al.  The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  David D. Smith,et al.  Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  K. Rezvani,et al.  Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  J. Madrigal,et al.  Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Lee,et al.  Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  H. Mayani,et al.  Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation , 2006, Annals of Hematology.

[23]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  S. Dubey,et al.  Expression of interferon-γ and tumor necrosis factor-α in bone marrow T cells and their levels in bone marrow plasma in patients with aplastic anemia , 2005, Annals of Hematology.

[25]  R. Negrin,et al.  Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. , 2005, Blood.

[26]  S. E. Jacobsen,et al.  IFN-γ Negatively Modulates Self-Renewal of Repopulating Human Hemopoietic Stem Cells1 , 2005, The Journal of Immunology.

[27]  A. Dispenzieri,et al.  The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma , 2004, Leukemia.

[28]  C. Mullighan,et al.  Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation , 2004, Transplantation.

[29]  S. Ansell,et al.  Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma , 2004, Bone Marrow Transplantation.

[30]  S. Markovic,et al.  Re-infused Autologous Graft Natural Killer Cells Correlates with Absolute Lymphocyte Count Recovery after Autologous Stem Cell Transplantation , 2003, Leukemia & lymphoma.

[31]  I. Dybedal,et al.  Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells. , 2001, Blood.

[32]  S. Davies,et al.  Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. , 1999, Blood.

[33]  M. Mielcarek,et al.  Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. , 1997, Blood.

[34]  N. Young,et al.  Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. , 1995, Blood.

[35]  T. Habermann,et al.  Evaluation of the Coulter Counter model S-Plus IV. , 1985, American journal of clinical pathology.

[36]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[37]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[38]  G. Morgan,et al.  High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD , 2013, Clinical transplantation.

[39]  S. Dubey,et al.  Expression of interferon-gamma and tumor necrosis factor-alpha in bone marrow T cells and their levels in bone marrow plasma in patients with aplastic anemia. , 2005, Annals of hematology.

[40]  R. Zulli,et al.  The influence of the graft monocytes in the outcome of allogeneic bone marrow transplantation. , 2002, Haematologica.